> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIO Suggests Improvements to 3 Covid-19 Guidances
- URL: https://www.fdaweb.com/bio-suggests-improvements-to-3-covid-19-guidances/
- Published: 2021-07-15T12:00:00.000Z
- Updated: 2026-09-14T17:06:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149723

BIO says an FDA Covid-19 emergency guidance, *Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the Covid-19 Public Health Emergency*, provides clarity on inspection activities during the Covid-19 pandemic and is an important step in discussions on modernizing inspectional activities. The association’s 7/14 comment [letter](https://downloads.regulations.gov/FDA-2020-D-1136-0071/attachment%5F1.pdf?ref=fdaweb.com) says that many of the concepts introduced in the guidance should be retained after the public health emergency ends and “become another set of tools in FDA’s toolbox for inspectional activities, utilizing a risk-based approach.”

The letter says BIO has identified areas where additional clarification or detail would be helpful, particularly as it relates to the final remote interactive evaluation report.

BIO also comments on two other emergency guidances — *Manufacturing, Supply Chain, and Drug and Biological Product Inspections During Covid-19 Public Health Emergency Questions and Answers* and *Resiliency Roadmap for FDA Inspectional Oversight*.